ArticleTranslational cancer research2026
FBXO17 regulates the malignant progression of colorectal cancer via the Wnt/β-catenin pathway.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) is one of the most common malignant tumors worldwide, often presenting without apparent early symptoms, and most patients are diagnosed at an advanced stage with a poor prognosis. F-box protein 17 (FBXO17) is up-regulated in various tumors and may represent a potential prognostic marker in CRC. This study sought to elucidate FBXO17's specific role in CRC and the underlying mechanism. Methods: Real-time fluorescence quantitative polymerase chain reaction (RT-qPCR), together with Western blot, was applied to determine FBXO17 expression in CRC cell lines. FBXO17-silenced and FBXO17-overexpressing CRC cells were established using a lentiviral system and liposome transfection technology, respectively. Cell counting kit-8, Transwell, and wound healing assays, as well as Western blot, were used to assess CRC cell proliferation, invasion, and migration, and to examine Wnt/β-catenin pathway activation. Intracellular reactive oxygen species (ROS), Fe Results: Compared with human normal colon cells, human CRC cells exhibited generally high FBXO17 expression. Silencing FBXO17 led to decreased CRC cell proliferation, invasion, and migration, attenuated Wnt/β-catenin pathway activation, and enhanced ferroptosis, whereas overexpression of FBXO17 reversed these effects by enhancing CRC cell proliferation, invasion, and migration, activating the Wnt/β-catenin pathway, and suppressing ferroptosis. Furthermore, treatment with ferrostatin-1 (ferroptosis inhibitor) or CHIR-99021 (Wnt/β-catenin pathway agonist) enhanced the proliferation, invasion, and migration of FBXO17-silenced CRC cells while attenuating ferroptosis. Conclusions: Silencing FBXO17 can promote CRC cell ferroptosis but inhibit proliferation, invasion, and migration through suppression of Wnt/β-catenin pathway activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.